ARTICLE | Company News

Dynogen, Mitsubishi Pharma deal

November 8, 2004 8:00 AM UTC

Dynogen received an exclusive license to Mitsubishi's pumosetrag, a prokinetic compound that Dynogen plans to develop for gastrointestinal conditions. Mitsubishi, which ran Phase II trials of the compound in undisclosed indications, retains rights to pumosetrag in Japan and other Asian countries. Dynogen expects to start clinical trials of pumosetrag for GI disorders in 2005. ...